West Pharmaceutical Services, I 🇺🇸
WST • Technology • USA
📊 Proprietary 12-Point Fundamental Audit
| Audit Dimension | Benchmark Criterion | WST Actual | Evaluation |
|---|---|---|---|
| 1. Economic Moat Strength | Software lock-in / high switching barrier / patent moat | Moat Score 92.9/100 | ✅ WIDE MOAT |
| 2. Pricing Power & Margins | Gross Margin > 40% sustainable | 36.8% Gross Margin | ⚠️ MODERATE |
| 3. Revenue Acceleration | YoY Top-Line Growth > 15% | +13.8% YoY | ⚠️ IN-LINE |
| 4. Peter Lynch PEG Ratio | PEG < 1.2x (Growth at a Reasonable Price) | 2.73x PEG Ratio | ⚠️ ELEVATED |
| 5. Fortress Balance Sheet | Debt / EBITDA < 2.5x | 0.3x Net Leverage | ✅ PASSED |
| 6. Free Cash Flow Generation | Positive and compounding FCF | $277.9M Free Cash Flow | ✅ PASSED |
| 7. Multiple vs Sector Median | Forward P/E reasonable vs earnings growth | Forward P/E: 37.7x | ✅ ATTRACTIVE MULTIPLE |
| 8. Management & Insider Ownership | Insider Ownership > 3% | 0.6% Insider Equity | ℹ️ INSTITUTIONAL |
| 9. Superinvestor Whale Backing | Held by Top 25 13F Wall St Whales | Institutional Superinvestor Interest | ℹ️ SCREENED |
| 10. Secular Industry Tailwinds | Exposure to multi-year compound themes | Technology sector expansion | ✅ PASSED |
| 11. Trailing P/E Multiple | Historical earnings multiple sanity | Trailing P/E: 43.2x | ✅ PASSED |
| 12. Overall Moat Conviction | Composite algorithmic evaluation | Overall Score: 92.9/100 | ✅ HIGH CONVICTION |
📝 MoatPicks Investment Thesis
Competitive Moat Breakdown: Provides the specialized glass vials required for GLP-1 weight loss drugs.
Valuation Verdict: Trading at a Forward P/E of 37.7x and PEG ratio of 2.73x, West Pharmaceutical Services, I satisfies core fundamental screens for quality and durability.
📊 Frequently Asked Questions & Related Moat Stocks
1. What is West Pharmaceutical Services, I (WST)'s Economic Moat Score in 2026?
In 2026, West Pharmaceutical Services, I (WST) holds a proprietary MoatPicks Economic Moat Score™ of 92.9/100 (Wide Economic Moat). This 12-point fundamental audit evaluates WST's 36.8% gross margin, $277.9M free cash flow generation, +13.8% YoY revenue growth, and 0.3x Debt/EBITDA ratio. You can benchmark any stock's competitive durability interactively with our Economic Moat Score™ Checker.
2. Is WST stock undervalued right now based on P/E and PEG ratio?
West Pharmaceutical Services, I (WST) commands a quality valuation premium at a Forward P/E of 37.7x and PEG ratio of 2.73x, reflecting its 36.8% gross margin and fortress cash flows. At a share price of $337.47, investors can stress-test WST's fair value using the MoatPicks Economic Moat Score™ Checker and FIRE compounding calculators. Model how compounding WST fits your long-term retirement target in our FIRE Financial Independence Calculator.
3. Which superinvestors and 13F hedge funds own WST stock?
West Pharmaceutical Services, I (WST) is actively monitored across our 25 tracked 13F superinvestor portfolios and institutional quality screens. Institutional capital focuses on WST's 36.8% gross margin, $277.9M free cash flow, and 0.3x Debt/EBITDA balance sheet.